New 'Double-Target' cell therapy tested for tough leukemia cases
NCT ID NCT06880913
Summary
This study is testing a new type of CAR-T cell therapy designed to attack leukemia cells using two targets (CD19 and CD22) at once. It aims to see if this approach is safe and effective for patients aged 12-65 whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments, including previous immunotherapies. The research will first find the safest dose and then see how well the therapy works at that dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deparment of Hematology, Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.